COMP <GO>
DMRA vs KRSA // EV/EBITDA & P/E VALUATION
Damora Therapeutics Inc. (NASDAQ) VS. Korsana Biosciences Inc. (NASDAQ) • 15-METRIC TALLY: DMRA 1
— KRSA 3
■ METRIC PARITY
LAST: $22.01 (+1.85%) • MKT CAP: $1.36B
valuation
—
LAST: $30.22 (+0.37%) • MKT CAP: $1.38B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DMRA VS. KRSA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | DMRA | KRSA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -5.70% | -29.30 | KRSA | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.49% | -0.24% | -0.25 | KRSA | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 3.70% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 2/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.8 | 45.6 | +4.21 | DMRA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.36B | $1.38B | -$17.5M | KRSA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | DMRA REV | KRSA REV | DMRA GROSS % | KRSA GROSS % | DMRA FCF | KRSA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $2.1M | — | — | -$6.7M | -$3.3M |
| FY 2024 | $0 | $2.0M | — | — | -$18.6M | -$4.3M |
| FY 2023 | $0 | $0 | — | — | -$36.9M | -$21.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DMRA // BETA —
KRSA // BETA —